Press coverage about BioMarin Pharmaceutical (NASDAQ:BMRN) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a news impact score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.475013147322 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 24, 2017 (finance.yahoo.com)
- Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ready for a Breakout? – FLBC News (flbcnews.com)
- Current Technical Chart Facts: BioMarin Pharmaceutical Inc. (BMRN), Square, Inc. (SQ) – AllStockNews (allstocknews.com)
- BioMarin Pharmaceutical’s (BMRN) “Equal Weight” Rating Reaffirmed at Barclays PLC (americanbankingnews.com)
- BMO Adjusts Its Outlook for 2 Pharma Stocks – Schaeffers Research (blog) (schaeffersresearch.com)
A number of research analysts recently issued reports on the company. BidaskClub downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday. Barclays PLC restated an “equal weight” rating and set a $100.00 price target (down previously from $105.00) on shares of BioMarin Pharmaceutical in a research note on Saturday. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Leerink Swann restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 18th. Finally, ValuEngine downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. BioMarin Pharmaceutical presently has an average rating of “Hold” and an average target price of $111.05.
BioMarin Pharmaceutical (BMRN) traded down 1.38% during trading on Tuesday, hitting $88.77. The stock had a trading volume of 338,639 shares. The stock’s market cap is $15.49 billion. BioMarin Pharmaceutical has a 1-year low of $78.42 and a 1-year high of $102.49. The firm’s 50-day moving average price is $90.74 and its 200-day moving average price is $90.01.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.33. BioMarin Pharmaceutical had a negative return on equity of 22.71% and a negative net margin of 48.43%. The company had revenue of $303.70 million during the quarter, compared to the consensus estimate of $292.58 million. During the same quarter in the prior year, the firm earned ($0.53) EPS. The company’s quarterly revenue was up 28.3% compared to the same quarter last year. On average, equities research analysts predict that BioMarin Pharmaceutical will post ($0.85) earnings per share for the current fiscal year.
In other news, EVP George Eric Davis sold 9,844 shares of the stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $96.60, for a total transaction of $950,930.40. Following the completion of the sale, the executive vice president now owns 93,425 shares in the company, valued at approximately $9,024,855. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey Robert Ajer sold 302 shares of the stock in a transaction on Tuesday, May 2nd. The shares were sold at an average price of $96.74, for a total value of $29,215.48. Following the sale, the executive vice president now owns 51,834 shares of the company’s stock, valued at approximately $5,014,421.16. The disclosure for this sale can be found here. Insiders have sold a total of 87,024 shares of company stock valued at $8,066,526 in the last quarter. Insiders own 2.50% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.